2-(1-Azidoethyl)-4-methylbenzenesulfonic acid

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-(1-Azidoethyl)-4-methylbenzenesulfonic acid
• 英文别名: 2-(1-azidoethyl)-4-methylbenzenesulfonic acid
• 化学式: C9H11N3O3S
• 分子量: 241.27
• InChiKey: MAEDHSIOEUPVEP-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.3
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  77.1
• 氢给体数：
  1
• 氢受体数：
  5

文献信息

• RADIOLABELED ANALOG(S) OF COMPOUND 0118 AND USE THEREOF IN CONNECTION WITH PET AND/OR SPECT IMAGING TO DETERMINE WHETHER A PHARMACEUTICAL CONTAINING COMPOUND 0118 IS A CANDIDATE CANCER TREATMENT FOR A PATIENT
  申请人：KONINKLIJKE PHILIPS N.V.

  公开号：US20150147273A1

  公开（公告）日：2015-05-28

  A method for determining whether compound 0118 is a candidate treatment for a patient includes processing, via a processor, image data of tissue of interest of a patient including a cancer to determine whether a radiolabeled analog of compound 0118 is present in the tissue of interest represented in the image data and generating a signal indicating that compound 0118 is a candidate treatment for the patient in response to the determining that the radiolabeled analog of compound 0118 is present in a predetermined amount in the tissue of interest represented in the image data, wherein the presence of the radiolabeled analog of compound 0118 in the tissue of interest indicates presence of a sub-type of cancer having a galectin-1 molecular target, which is a sub-type of treatable by compound 0118.

  一种确定化合物0118是否是患者的候选治疗方法，包括通过处理器处理患者感兴趣的组织的图像数据，包括癌症，以确定化合物0118的放射性标记类似物是否存在于图像数据中所代表的感兴趣的组织中，并生成一个信号，指示化合物0118是患者的候选治疗，以响应于确定放射性标记类似物在图像数据中所代表的感兴趣的组织中以预定量存在，其中放射性标记类似物在感兴趣的组织中的存在表示存在具有galectin-1分子靶标的癌症亚型，该亚型可以通过化合物0118进行治疗。
• [EN] RADIOLABELED ANALOG(S) OF COMPOUND 0118 AND USE THEREOF IN CONNECTION WITH PET AND/OR SPECT IMAGING TO DETERMINE WHETHER A PHARMACEUTICAL CONTAINING COMPOUND 0118 IS A CANDIDATE CANCER TREATMENT FOR A PATIENT<br/>[FR] ANALOGUE(S) RADIOMARQUÉ(S) D'UN COMPOSÉ 0118 ET SON/LEUR UTILISATION EN CONNEXION AVEC L'IMAGERIE PET ET/OU SPECT POUR DÉTERMINER SI UN PRODUIT PHARMACEUTIQUE CONTENANT LE COMPOSÉ 0118 EST UN TRAITEMENT ANTICANCÉREUX CANDIDAT POUR UN PATIENT
  申请人：KONINKL PHILIPS NV

  公开号：WO2013186690A2

  公开（公告）日：2013-12-19

  A method for determining whether compound 0118 is a candidate treatment for a patient includes processing, via a processor, image data of tissue of interest of a patient including a cancer to determine whether a radiolabeled analog of compound 0118 is present in the tissue of interest represented in the image data and generating a signal indicating that compound 0118 is a candidate treatment for the patient in response to the determining that the radiolabeled analog of compound 0118 is present in a predetermined amount in the tissue of interest represented in the image data, wherein the presence of the radiolabeled analog of compound 0118 in the tissue of interest indicates presence of a sub-type of cancer having a galectin-1 molecular target, which is a sub-type of treatable by compound 0118.